D. E. Shaw & Co., Inc. - CATALYST PHARMACEUTICALS INC ownership

CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 190 filers reported holding CATALYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of CATALYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$1,777,675
-64.8%
152,068
-59.5%
0.00%
-60.0%
Q2 2023$5,048,306
-74.2%
375,618
-68.2%
0.01%
-76.2%
Q1 2023$19,554,817
-35.3%
1,179,422
-27.4%
0.02%
-36.4%
Q4 2022$30,205,768
+26.2%
1,623,966
-12.9%
0.03%
+13.8%
Q3 2022$23,928,000
+139.2%
1,865,025
+30.7%
0.03%
+141.7%
Q2 2022$10,004,000
+15.8%
1,427,050
+37.0%
0.01%
+50.0%
Q1 2022$8,638,000
+123.1%
1,041,967
+82.2%
0.01%
+166.7%
Q4 2021$3,871,000
+80.4%
571,787
+41.2%
0.00%
+50.0%
Q3 2021$2,146,000
-17.5%
404,858
-10.5%
0.00%0.0%
Q2 2021$2,601,000
+275.3%
452,338
+200.8%
0.00%
+100.0%
Q1 2021$693,000
-41.9%
150,392
-57.9%
0.00%0.0%
Q4 2020$1,192,000
-11.9%
356,947
-21.7%
0.00%0.0%
Q3 2020$1,353,000
-59.2%
455,804
-36.5%
0.00%
-75.0%
Q2 2020$3,317,000
+3.2%
718,034
-14.0%
0.00%
-20.0%
Q1 2020$3,214,000
+41.8%
834,597
+38.1%
0.01%
+66.7%
Q4 2019$2,267,000
+1728.2%
604,435
+1748.8%
0.00%
Q3 2018$124,000
-29.1%
32,694
-41.7%
0.00%
Q2 2018$175,000
-32.7%
56,122
-48.5%
0.00%
Q1 2018$260,000
-36.7%
108,948
+3.6%
0.00%
-100.0%
Q4 2017$411,000
+3061.5%
105,148
+731.1%
0.00%
Q4 2016$13,000
-43.5%
12,651
-61.8%
0.00%
Q2 2016$23,000
-95.6%
33,094
-92.6%
0.00%
-100.0%
Q1 2016$525,000
-32.3%
448,333
+41.7%
0.00%0.0%
Q4 2015$775,000
+85.9%
316,465
+127.9%
0.00%0.0%
Q3 2015$417,000
-51.0%
138,845
-32.6%
0.00%0.0%
Q2 2015$851,000206,1030.00%
Other shareholders
CATALYST PHARMACEUTICALS INC shareholders Q1 2022
NameSharesValueWeighting ↓
TANAKA CAPITAL MANAGEMENT INC 148,281$2,4587.14%
GABLES CAPITAL MANAGEMENT INC. 409,080$6,782,5464.74%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 10,355,099$171,687,5413.83%
JW Asset Management, LLC 563,392$9,341,0393.58%
Quantedge Capital Pte Ltd 324,700$5,383,5262.10%
Paradiem, LLC 236,628$3,923,2921.22%
SummerHaven Investment Management, LLC 100,592$1,667,8150.97%
Capital Impact Advisors, LLC 46,096$764,2720.94%
Yorktown Management & Research Co Inc 50,000$829,0000.89%
Seaport Global Advisors, LLC 15,598$258,6150.82%
View complete list of CATALYST PHARMACEUTICALS INC shareholders